Siga Technologies Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Siga Technologies Inc in the second quarter 2026?
Siga Technologies Inc achieved a return on average equity (ROE) of 6.74 % in its second quarter 2026, which is below Siga Technologies Inc's average return on equity, which stands at 46.04%.

ROE fell compared to the first quarter 2026, despite the net income growth of % from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 57 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1354, from total ROE ranking in the first quarter 2026 at 1356.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-21.03 %	-29.85 %	-7.87 %	20.09 %	-
Y / Y Net Income Change	-22.88 %	-	-	-	1836.2 %
Net Income (TTM) in Millions	12	20	23	74	82
Return On Equity (TTM)	6.74 %	10.6 %	11.25 %	35.26 %	40.55 %
SIGA's Total Ranking	# 1354	# 1356	# 964	# 232	# 189
Equity (TTM) in Millions	165	152	199	203	209
Seq. Equity Change	9.02 %	-23.74 %	-2.29 %	-2.79 %	-3.16 %
Seq. Net Income Change	-	-	-	-	-

Back to SIGA Management Effectiveness >> SIGA's 5 Years Annual ROE >> Compare SIGA ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 58
Sector	# 161
Overall	# 1354

Return On Equity Statistics
High	Average	Low
481.11 %	46.04 %	-17.74 %
(Jun 30 2019)		(Mar 31 2020)

News about Siga Technologies Inc Return on Equity ROE

TEPOXX Takes Center Stage: A New Dawn in the Fight Against Orthopoxviruses,

Expansion of TEPOXX (Tecovirimat) Approval Signals Hope Against Orthopoxvirus ThreatsIn a landmark decision, SIGA Technologies has announced that its antiviral treatment, TEPOXX (tecovirimat), has been officially approved in Japan for addressing a range of orthopoxvirus infections. This announcement, made on January 2, 2025, confirms TEPOXX as a significant therapeutic option for smallpox, mpox (formerly known as monkeypox), and cowpox, as well as for managing complications arising from smallpox vaccination. Regulatory Approval and Its SignificanceThe approval by Japan s Pharmaceuticals and Medical Devices Agency (PMDA), in conjunction with the Ministry of Health, Labour and Welfare, marks TEPOXX as the first antiviral therapy authorized for treating infections caused by orthopoxviruses in Japan. The approval extends to both adults and pediatric patients who weigh at least 13 kilograms, enhancing the pharmaceutical landscape in Japan and potentially offering new treatment pathways for diseases previously seen as historical threats. Financial Resilience of SIGA TechnologiesIn addition to the therapeutic advancements, SIGA Technologies has demonstrated robust financial performance. In the third quarter of 2024, the company reported an impressive return on equity (ROE) of 49.06%, significantly surpassing its average historical ROE of 8.84%. This strong financial standing indicates the company s ability to invest in research, development, and global market expansion, fostering optimism about its future.

SIGA Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	199	216	197	170	174
Y / Y Equity Change	-7.87 %	9.62 %	15.69 %	-2.38 %	34.3 %
Net Income in Millions	23	59	68	34	69
Y / Y Net Income Change	-60.69 %	-13.01 %	100.76 %	-51.18 %	23.27 %
Return On Equity	11.71 %	27.44 %	34.58 %	19.93 %	39.84 %

Back to SIGA Management Effectiveness >> SIGA's 5 Years Annual ROE >> Compare SIGA ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 11.71 %, due to deterioration of net income.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SIGA's' Return on Equity at Yahoo Finance
SIGA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SIGA's Competitors
Subscribers only: Roe for Siga Technologies Inc's Suppliers
Subscribers only: Return On Equity for SIGA's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
West Pharmaceutical Services Inc	18.51 %
Intuitive Surgical Inc	17.82 %
Standard Biotools Inc	17.64 %
Inspire Medical Systems inc	17.62 %
Medinotec Inc	17.47 %
Lemaitre Vascular Inc	16.93 %
Ufp Technologies Inc	16.72 %
Ensign Group Inc	16.53 %
Stryker Corp	16.36 %
Nephros Inc	16.20 %
Spero Therapeutics Inc	16.17 %
Progyny Inc	15.98 %
Collegium Pharmaceutical Inc	15.96 %
Alpha Pro Tech Ltd	15.43 %
Livanova Plc	15.41 %
Biolife Solutions Inc	15.28 %
Lifevantage Corp	15.06 %
Quest Diagnostics Inc	14.85 %
Infusystem Holdings Inc	14.81 %
Boston Scientific Corporation	14.77 %
Strata Critical Medical Inc	14.27 %
Beone Medicines Ltd	14.24 %
Royalty Pharma Plc	13.82 %
Regeneron Pharmaceuticals Inc	13.81 %
National Healthcare Corp	13.11 %
Kewaunee Scientific Corporation	12.61 %
Protagonist Therapeutics inc	11.80 %
Entrada Therapeutics Inc	11.77 %
Haemonetics Corporation	11.66 %
Globus Medical Inc	11.59 %

Date modified: 2026-09-08T22:13:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.